News and reporting on cell-free DNA testing.
Last year, the company processed more than 1 million tests, most of them for its reproductive health business, but interest in Prospera and Signatera is growing.
The company had been working to expand its retrospective data over the last year and half and is now readying to move forward with prospective studies.
The company intends to develop its fragmentomic approach for early cancer detection both in individual tumor types and for multi-cancer screening.
Backed by large public companies and growing prospective data, the first molecular blood tests to screen for multiple cancers are approaching commercialization.
The liquid biopsy test, Colvera, detects aberrant methylation in BCAT1 and IKZF1, two genes found at a high frequency in colorectal cancer tissue.
